Global Chronic Ocular Surface Pain Market is valued at approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. Chronic Ocular Surface Pain is a condition that occurs due to the damage of tissue at the ocular surface or from variations to central or peripheral nerves in the ocular surface sensory pathway. The rising prevalence of bacterial and viral ocular infections, increasing geriatric populations, and growing incidences of dry eyes among people, coupled with the rise in healthcare expenditure are several factors fostering the market demand across the globe. For instance, according to the World Health Organization (WHO), the geriatric population around the world is estimated to be over 524 million in 2010, and it is projected to increase to nearly 2 billion by 2050. Consequentially, aged people are more prone to suffer from various eye disorders, which, in turn, augment the market growth across the globe. However, the shortage of skilled professionals and the unavailability of advanced healthcare facilities in developing economies impede the growth of the market over the forecast period of 2022-2028. Also, a rise in the number of research and development activities and increasing drug approvals and launches are anticipated to act as catalyzing factors for the market demand during the forecast period.
The key regions considered for the global Chronic Ocular Surface Pain Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the increasing technological developments in diagnostic procedures and growing healthcare expenditure. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the rising prevalence of ocular diseases, as well as, rising presence of major generic manufacturers, would create lucrative growth prospects for the Chronic Ocular Surface Pain Market across the Asia-Pacific region.
Major market players included in this report are:
Pfizer Inc.
Novartis AG
Zydus Cadila
AstraZeneca
Johnson & Johnson
Bayer AG
Sun Pharmaceutical Industries Ltd.
Bristol-Myers Squibb Company
Eli Lilly and Company
LEO Pharma A/S
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
Antibiotics
Nonsteroidal Anti-Inflammatory (NSAID)
Corticosteroids
Others
By Application:
Sinusitis
Migraines
Glaucoma
Others
By End-Users:
Hospitals
Specialty Clinics
Homecare
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2018, 2019, 2020
Base year - 2021
Forecast period - 2022 to 2028
Target Audience of the Global Chronic Ocular Surface Pain Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
- 1.2.1. Chronic Ocular Surface Pain Market, by Region, 2020-2028 (USD Million)
- 1.2.2. Chronic Ocular Surface Pain Market, by Drug Class, 2020-2028 (USD Million)
- 1.2.3. Chronic Ocular Surface Pain Market, by Application, 2020-2028 (USD Million)
- 1.2.4. Chronic Ocular Surface Pain Market, by End-Users, 2020-2028 (USD Million)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Chronic Ocular Surface Pain Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Scope of the Study
- 2.2.2. Industry Evolution
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Chronic Ocular Surface Pain Market Dynamics
- 3.1. Chronic Ocular Surface Pain Market Impact Analysis (2020-2028)
- 3.1.1. Market Drivers
- 3.1.1.1. Rising prevalence of bacterial and viral ocular infections
- 3.1.1.2. Growing geriatric populations
- 3.1.2. Market Challenges
- 3.1.2.1. Shortage of skilled professionals
- 3.1.2.2. Unavailability of advanced healthcare facilities in developing economies
- 3.1.3. Market Opportunities
- 3.1.3.1. Rise in the number of research and development activities
- 3.1.3.2. Increasing drug approvals and launches
Chapter 4. Global Chronic Ocular Surface Pain Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
- 4.2. PEST Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.3. Investment Adoption Model
- 4.4. Analyst Recommendation & Conclusion
- 4.5. Top investment opportunity
- 4.6. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
- 5.1.1. Assessment of the overall impact of COVID-19 on the industry
- 5.1.2. Pre COVID-19 and post COVID-19 market scenario
Chapter 6. Global Chronic Ocular Surface Pain Market, by Drug Class
- 6.1. Market Snapshot
- 6.2. Global Chronic Ocular Surface Pain Market by Drug Class, Performance - Potential Analysis
- 6.3. Global Chronic Ocular Surface Pain Market Estimates & Forecasts by Drug Class, 2018-2028 (USD Million)
- 6.4. Chronic Ocular Surface Pain Market, Sub Segment Analysis
- 6.4.1. Antibiotics
- 6.4.2. Nonsteroidal Anti-Inflammatory (NSAID)
- 6.4.3. Corticosteroids
- 6.4.4. Others
Chapter 7. Global Chronic Ocular Surface Pain Market, by Application
- 7.1. Market Snapshot
- 7.2. Global Chronic Ocular Surface Pain Market by Application, Performance - Potential Analysis
- 7.3. Global Chronic Ocular Surface Pain Market Estimates & Forecasts by Application, 2018-2028 (USD Million)
- 7.4. Chronic Ocular Surface Pain Market, Sub Segment Analysis
- 7.4.1. Sinusitis
- 7.4.2. Migraines
- 7.4.3. Glaucoma
- 7.4.4. Others
Chapter 8. Global Chronic Ocular Surface Pain Market, by End-Users
- 8.1. Market Snapshot
- 8.2. Global Chronic Ocular Surface Pain Market by End-Users, Performance - Potential Analysis
- 8.3. Global Chronic Ocular Surface Pain Market Estimates & Forecasts by End-Users, 2018-2028 (USD Million)
- 8.4. Chronic Ocular Surface Pain Market, Sub Segment Analysis
- 8.4.1. Hospitals
- 8.4.2. Specialty Clinics
- 8.4.3. Homecare
- 8.4.4. Others
Chapter 9. Global Chronic Ocular Surface Pain Market, Regional Analysis
- 9.1. Chronic Ocular Surface Pain Market, Regional Market Snapshot
- 9.2. North America Chronic Ocular Surface Pain Market
- 9.2.1. U.S. Chronic Ocular Surface Pain Market
- 9.2.1.1. Drug Class breakdown estimates & forecasts, 2018-2028
- 9.2.1.2. Application breakdown estimates & forecasts, 2018-2028
- 9.2.1.3. End-Users breakdown estimates & forecasts, 2018-2028
- 9.2.2. Canada Chronic Ocular Surface Pain Market
- 9.3. Europe Chronic Ocular Surface Pain Market Snapshot
- 9.3.1. U.K. Chronic Ocular Surface Pain Market
- 9.3.2. Germany Chronic Ocular Surface Pain Market
- 9.3.3. France Chronic Ocular Surface Pain Market
- 9.3.4. Spain Chronic Ocular Surface Pain Market
- 9.3.5. Italy Chronic Ocular Surface Pain Market
- 9.3.6. Rest of Europe Chronic Ocular Surface Pain Market
- 9.4. Asia-Pacific Chronic Ocular Surface Pain Market Snapshot
- 9.4.1. China Chronic Ocular Surface Pain Market
- 9.4.2. India Chronic Ocular Surface Pain Market
- 9.4.3. Japan Chronic Ocular Surface Pain Market
- 9.4.4. Australia Chronic Ocular Surface Pain Market
- 9.4.5. South Korea Chronic Ocular Surface Pain Market
- 9.4.6. Rest of Asia Pacific Chronic Ocular Surface Pain Market
- 9.5. Latin America Chronic Ocular Surface Pain Market Snapshot
- 9.5.1. Brazil Chronic Ocular Surface Pain Market
- 9.5.2. Mexico Chronic Ocular Surface Pain Market
- 9.6. Rest of The World Chronic Ocular Surface Pain Market
Chapter 10. Competitive Intelligence
- 10.1. Top Market Strategies
- 10.2. Company Profiles
- 10.2.1. Pfizer Inc.
- 10.2.1.1. Key Information
- 10.2.1.2. Overview
- 10.2.1.3. Financial (Subject to Data Availability)
- 10.2.1.4. Product Summary
- 10.2.1.5. Recent Developments
- 10.2.2. Novartis AG
- 10.2.3. Zydus Cadila
- 10.2.4. AstraZeneca
- 10.2.5. Johnson & Johnson
- 10.2.6. Bayer AG
- 10.2.7. Sun Pharmaceutical Industries Ltd.
- 10.2.8. Bristol-Myers Squibb Company
- 10.2.9. Eli Lilly and Company
- 10.2.10. LEO Pharma A/S
Chapter 11. Research Process
- 11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
- 11.2. Research Attributes
- 11.3. Research Assumption